NCT03591224View on ClinicalTrials.gov

Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

NACompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
DepressionAnxietyMajor Depressive DisorderGeneralized Anxiety DisorderMood Disorders
Interventions
OTHER

Pharmacogenomic Testing

pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism

OTHER

Pharmacist Standard of Care

Pharmacist providing standard of care as per usual practice

Trial Locations (2)

M4C 1H6

John Papastergiou Pharmacy Ltd - Store#500, Toronto

M4J 1L2

John Papastergiou Pharmacy Ltd - Store#994, Toronto

All Listed Sponsors
collaborator

Green Shield Canada

UNKNOWN

lead

John Papastergiou Pharmacy Ltd

INDUSTRY

NCT03591224 - Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy | Biotech Hunter | Biotech Hunter